- Active Pharmaceutical Ingredients
- Varenicline tartrate
- Aprepitant, Fosapitant Intermediates
- Fosaprepitant Dimeglumine
- Vildagliptin
- Efinaconazole
- Luliconazole Intermediate
- Gadoterate Meglumine
- Succinyl Alcohol Intermediate
- Mirabillon Intermediate
- Atazanavir Intermediate
- Intermediate
- Varenicline tartrate
- Aprepitant 287930-73-8
- Aprepitant 127852-28-2
- Aprepitant 287930-75-0
- Aprepitant 200000-59-5
- Aprepitant 155742-64-6
- Aprepitant 252742-72-6
- Fosaprepitant Dimeglumine 990-91-0
- Fosaprepitant Dimeglumine 265121-01-5
- Vildagliptin 207557-35-5
- Vildagliptin 702-82-9
- Efinaconazole 144230-50-2
- Efinaconazole 133775-25-4
- Efinaconazole 127000-90-2
- Gadoterate Meglumine
- Mirabegron
- Luliconazole 98873-55-3
- Luliconazole 126534-31-4
- Atazanavir sulfate
- Bortezomib 179324-87-9
- Bortezomib 114457-94-2
- Bortezomib 205393-22-2
- Brinzolamide
- Rivaroxaban Intermediate 446292-08-6
- Rivaroxaban Intermediate 446292-07-5
- Cinacalcet Hydrochloride 1005450-55-4
- Cinacalcet Hydrochloride 585-50-2
- Eletriptan Intermediate
- Indacaterol intermediate 312753-53-0
- Indacaterol intermediate 173140-90-4
- Sitagliptin Intermediate
- Fosanavir Calcium Intermediate
Popular information
Diabetes medication Vildagliptin 274901-16-5
【Catalog number】AP2401
【CAS #】654671-77-9
【Molecular formula】C16H20F6N5O6P
【Product Brief】CAS 274901-16-5 Vidagliptin, the English name is Vildagliptin, the American Chemical Abstracts registration number is cas 274901-16-5.
Alias (-)-(2S) -1-[[(3-hydroxytricyclo [3.3.1.1 [3,7]] silane-1-yl) amino] acetyl] pyrrolidine-2-carbonitrile; Vita Liptin; (-)-(2S) -1-[[(3-hydroxytricyclo [3.3.1.1 [3,7]] decane-1-yl) amino] acetyl] pyrrolidine-2-carbonitrile Vedagliptin Vedagliptin Vedagliptin
Catalog number AP2700
CAS # 274901-16-5
Molecular formula C17H25N3O2
Molecular weight 303.40
Structural formula
Product introduction
CAS 274901-16-5 Vidagliptin, the English name is Vildagliptin, the American Chemical Abstracts registration number is cas 274901-16-5.
Vinalitin (cas 274901-16-5) is a selective, competitive, and reversible DPP_4 inhibitor. By combining with DPP-4 to form a DPP-4 complex to inhibit the activity of the enzyme, while increasing the concentration of GLP-1 and promoting the production of insulin by islet B cells, it also lowers the concentration of glucagon, thereby reducing blood glucose, and has no effect on body weight. Significant impact. This product is an oral anti-diabetic drug.
VIWIT 沪ICP备12014533号-1
